Clinical trials: Tuberculosis, open to volunteers
HIV I Infection, Tuberculosis
Evaluating the Safety and Immunogenicity of MTBVAC
The purpose of this study is to evaluate the safety and immunogenicity of MTBVAC in adolescents and adults living with and without HIV in South Africa
- Trial name
- HVTN605A5421 (NCT05947890)
- Testing
- MTBVAC, BCG
- Where
- 16 sites in South Africa
- Volunteers
- 276 people, healthy volunteers welcome
- Sponsor
- HIV Vaccine Trials Network
Mycobacterium Infections, Tuberculosis, Multidrug-Resistant
Training Protocol on the Natural History of Tuberculosis
Background: Tuberculosis (TB) is an infectious disease that affects numerous people worldwide. Researchers are interested in actively recruiting individuals with TB for research and treatment studies.
- Conditions
- Mycobacterium Infections, Tuberculosis, Multidrug-Resistant, Latent Tuberculosis, Tuberculosis
- Trial name
- NCT01212003
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Multidrug-resistant Tuberculosis (MDR-TB)
Molecular Epidemiology, Strains Genotyping of Multi-drug Resistant Tuberculosis Circulating in Central Africa Region
Multidrug-resistant tuberculosis (MDR-TB) poses a significant challenge in Central Africa. Understanding the molecular epidemiology and genotypic characteristics of MDR-TB strains is crucial for effective control measures.
- Trial name
- MESTCAR (NCT07017803)
- Where
- 8 sites in Gabon
- Volunteers
- 460 people, healthy volunteers welcome
- Sponsor
- Centre de Recherche Médicale de Lambaréné
Tuberculosis, Extrapulmonary Tuberculosis
Biomarker Analysis for Diagnosing and Treatment Monitoring in Extrapulmonary Tuberculosis Patients in Nairobi, Kenya
Tuberculosis (TB) remains a global health threat with high incidence, especially in Africa. The proportion of extrapulmonary TB (EPTB) can escalate up to 36% in areas with a high HIV prevalence.
- Conditions
- Tuberculosis, Extrapulmonary Tuberculosis, Mycobacterium Tuberculosis
- Trial name
- BioTube (NCT07901387)
- Where
- 2 sites in Kenya
- Volunteers
- 700 people
- Sponsor
- Nagasaki University
Tuberculosis Diagnosis
Evaluation of New TB Diagnostic Tests (NATs) in Pakistan
This study evaluates two portable molecular tests for tuberculosis (TB), Pluslife MTBC and Ustar PortNAT, during community-based active case-finding activities in Pakistan.
- Trial name
- TB (NCT06984887)
- Testing
- Paired tongue-swab and sputum-based molecular testing for tuberculosis
- Where
- 2 sites in Pakistan
- Volunteers
- 6,100 people, healthy volunteers welcome
- Sponsor
- Mercy Corps Pakistan
Drug Resistant Tuberculosis
Bring BPaL2Me Trial Comparing Nurse-Led RR-TB Treatment to Physician-Led RR-TB Treatment
The goal of the BringBPaL2Me Trial, a multi-principal investigator, multi-site, cluster randomized, non-inferiority trial is to compare nurse-led RR-TB treatment in primary care clinics to standard of care physician-led RR-TB…
- Trial name
- NCT05671718
- Testing
- Nurse-Led Treatment in Primary Care
- Where
- 5 sites in South Africa
- Volunteers
- 2,944 people
- Sponsor
- Johns Hopkins University
Tuberculosis (TB)
Optimal Treatment Duration for Radiographically Apparent, Bacteriologically Unconfirmed TB, Identified Through Active Case Finding (RADIO-TB Trial)
People living in high TB burden communities who undergo active case finding for TB may have chest X-ray changes suggestive of TB but their sputum test can be negative for the TB bacteria or they are unable to provide a sputum…
- Trial name
- RADIO-TB (NCT07163143)
- Testing
- Isoniazid (H), Rifampicin (R), Pyrazinamide (Z)
- Where
- 4 sites in Pakistan, South Africa and 1 more
- Volunteers
- 784 people
- Sponsor
- University College, London
Rifampicin-Resistant Pulmonary Tuberculosis, Multidrug-Resistant Pulmonary Tuberculosis
A Study of Quabodepistat-containing Regimens for the Treatment of Drug-resistant Pulmonary Tuberculosis
This is a Phase 3, randomized, open-label, active-controlled, multicenter trial evaluating the efficacy, safety, and tolerability of quabodepistat-containing regimens for the treatment of rifampicin-resistant or…
- Trial name
- QUANTUM-TB (NCT07209761)
- Testing
- Bedaquiline, Quabodepistat, Pretomanid
- Where
- 42 sites in China, Georgia and 8 more
- Volunteers
- 532 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Tuberculosis
BRIGHT-Child TB: Short-Course Treatment for Non-Severe Pulmonary Tuberculosis in Children
The goal of this Phase II, multicenter, open-label, randomized controlled trial is to evaluate the efficacy and safety of short-course treatment regimens for children with non-severe, drug-susceptible pulmonary tuberculosis.
- Trial name
- NCT07893444
- Testing
- 4-month FDC-based regimen, 3-month BDCZ regimen, Standard 6-month treatment regimen
- Where
- 13 sites in China
- Volunteers
- 90 people
- Sponsor
- Huashan Hospital
Tuberculosis
ID93/GLA-SE Vaccination + BCG Challenge
The purpose of this study is to: 1. Demonstrate the safety of a novel TB vaccine (ID93/GLA-SE) when given to both BCG-vaccinated and BCG-naïve volunteers. 2.
- Trial name
- NCT06670755
- Testing
- ID93/GLA-SE, BCG Danish
- Where
- United Kingdom
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Drug-Induced Acute Liver Injury, Tuberculosis (TB)
Silymarin Versus N-Acetylcysteine as Protective Effect Against Anti-tuberculosis Drugs Induced Liver Injury.
Worldwide, tuberculosis (TB) infection caused by Mycobacterium Tuberculosis, remains one of the top 10 deadly diseases having a significant socioeconomic burden in the world, especially in developing countries.
- Trial name
- NCT07875322
- Testing
- Antituberculosis drugs Group
- Where
- Egypt
- Volunteers
- 102 people
- Sponsor
- Assiut University
Pulmonary Tuberculosis
Channa Striata and Curcuma Domestica Supplementation in Patients With Active Pulmonary Tuberculosis
This study aims to evaluate the effect of combined supplementation with Channa striata extract and Curcuma domestica rhizome on nutritional status, inflammatory markers, and quality of life in patients with active pulmonary…
- Trial name
- NCT07887724
- Testing
- CHANA STRIATA AND CURCUMA
- Where
- 2 sites in Indonesia
- Volunteers
- 80 people
- Sponsor
- DINA KEUMALA SARI
Tuberculosis, Latent
Bedaquiline Roll-out Evidence in Contacts and People Living With HIV to Prevent TB
A seamless, staged Phase II/III, open-label, multicenter, non-inferiority trial, to compare the efficacy and safety of 4 weeks of bedaquiline (BDQ) versus a a standard regimen for preventing regimen for preventing confirmed or…
- Trial name
- BREACH-TB (NCT06568484)
- Testing
- Bedaquiline, Isoniazid, rifapentine, Levofloxacin
- Where
- 8 sites in Mongolia, Peru and 2 more
- Volunteers
- 2,530 people
- Sponsor
- Johns Hopkins University
Tuberculosis
Paradoxical Tuberculosis Reactions in Patients Without HIV Infection
Background: Most people with tuberculosis (TB) feel better after starting treatment. But for some people, the opposite happens. They may feel better at first, but then suddenly get worse. This is a paradoxical reaction.
- Trial name
- NCT04052022
- Where
- 3 sites in United States, Mexico
- Volunteers
- 140 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Pulmonary Tuberculosis
Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis
A5409/RAD-TB is an adaptive Phase 2 randomized, controlled, open-label, dose-ranging, platform protocol to evaluate the safety and efficacy of multidrug regimens for the treatment of adults with drug-susceptible pulmonary…
- Trial name
- RAD-TB (NCT06192160)
- Testing
- Isoniazid, Rifampicin, Pyrazinamide
- Where
- 30 sites in Botswana, Brazil and 12 more
- Volunteers
- 315 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Tuberculosis
A Study of Daily Rifapentine Combined With Isoniazid (1HP) for Tuberculosis Prevention in Children Less Than 13 Years of Age With and Without HIV
This study aims to find the proposed dose of Rifapentine (RPT) taken once daily with Isoniazid (INH) for 28 days to prevent tuberculosis (TB).
- Trial name
- NCT07124559
- Testing
- Rifapentine, Isoniazid, Dolutegravir
- Where
- 11 sites in Botswana, Haiti and 4 more
- Volunteers
- 144 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Tuberculous Meningitis, HIV
BPaLMZ for TB Meningitis
This two-stage study will compare consented research participants with tuberculous meningitis receiving experimental Bedaquiline (B), Pretomanid (Pa), Linezolid (L); Moxifloxacin (M), Pyrazinamide (Z) known as (BPaLMZ) to…
- Conditions
- Tuberculous Meningitis, HIV, Meningitis, TB - Tuberculosis
- Trial name
- BPaLMZ (NCT07227779)
- Testing
- BPaLMZ Regimen
- Where
- 2 sites in Uganda
- Volunteers
- 312 people
- Sponsor
- David Boulware
Tuberculosis, Diagnostics
Rapid Research in Diagnostics Development for TB Network (R2D2 Kids) and Assessing Diagnostics At POC for TB in Children (ADAPT for Kids)
Every year there are an estimated 230,000 childhood deaths from TB. There is an urgent need for novel tests for TB diagnosis in children under 15 years.
- Conditions
- Tuberculosis, Diagnostics, Global Health
- Trial name
- NCT05989802
- Testing
- Oral swab molecular testing, Automated Cough Sound Analysis, Automated Lung Sound Analysis
- Where
- 3 sites in Mozambique, South Africa and 1 more
- Volunteers
- 2,100 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Pulmonary Tuberculosis
Platform Assessing Regimens and Durations In a Global Multisite Consortium for TB
The UNITE4TB consortium is a group of universities and pharmaceutical companies funded by the European Union. This consortium are carrying out a trial to find better and faster ways to treat tuberculosis (TB).
- Trial name
- PARADIGM4TB (NCT06114628)
- Testing
- Ganfeborole, BTZ-043, Bedaquiline (B)
- Where
- 11 sites in Moldova, South Africa and 3 more
- Volunteers
- 2,500 people
- Sponsor
- University College, London
Tuberculosis
Diagnostic Innovations for Pediatric Tuberculosis in Bolivia
Pediatric tuberculosis (TB) continues to pose diagnostic challenges in low- and middle-income countries with high rates of TB disease, due to the well-described impact of paucibacillary disease in children, and current TB culture…
- Trial name
- NCT06113861
- Testing
- Quantiferon Gold, HIV serology, Respiratory secretion culture (sputum or gastric aspirate_
- Where
- Bolivia
- Volunteers
- 1,220 people
- Sponsor
- Tulane University